Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

  • End date
    Jun 8, 2023
  • participants needed
  • sponsor
    City of Hope Medical Center
Updated on 25 March 2022
monoclonal antibodies
systemic therapy
serum pregnancy test
measurable disease
neutrophil count
monoclonal antibody therapy
chemotherapy regimen
monoclonal protein
skin biopsy
t-cell lymphoma
peripheral t-cell lymphoma
mycosis fungoides
sezary syndrome
anaplastic large cell lymphoma
microscopic examination
cutaneous lymphoma
cutaneous t-cell lymphoma


This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.



I. To determine the maximum tolerated dose (recommended phase 2 dose, RP2D) of lenalidomide, when given in combination with fixed-dose durvalumab. (Phase 1) II. To assess the safety and tolerability of the lenalidomide/durvalumab regimen, and accompanying dose modification plan, by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase 1) III. To evaluate the anti-tumor activity durvalumab (MEDI4736) as single agent therapy and as part of combination therapy (+lenalidomide); activity assessed by overall response rate (ORR). (Phase 2)


I. To estimate and assess response duration and survival probabilities (overall and event-free). (Phase 2) II. To summarize and assess toxicities by type, frequency, severity, attribution, time course and duration. (Phase 2) III. To assess clinically meaningful reduction in pruritus (CMRP) in patients with CTCL (critical quality of life measure). (Phase 2)


I. To identify the malignant CD4+ T cells within the skin microenvironment. II. To characterize the spatial and functional relationship of malignant T cells with other immune cells, their expression of key immune checkpoints and correlate with response.

III. To identify aberrantly expressed micro(mi) ribonucleic acid (RNA)s involved in cutaneous T-cell lymphoma (CTCL) and messenger (m)RNAs that may predict response and/or treatment-related toxicity.

IV. To evaluate whether or not the identified miRNAs are involved in regulating key immune checkpoints.

OUTLINE: This is a phase I, dose-escalation study of lenalidomide followed by a phase II study. Patients are randomized to 1 of 2 arms,

ARM I: Patients receive durvalumab intravenously (IV) over 1 hour on day 1. Treatment repeats every 28 days (+/- 3) for up to 13 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 12 months.

Condition Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Treatment laboratory biomarker analysis, Lenalidomide, durvalumab
Clinical Study IdentifierNCT03011814
SponsorCity of Hope Medical Center
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative
Registered into Revlimid REMS program
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1
Relapsed/refractory disease
Failed >= 2 prior systemic therapies NOTE: For systemic ALCL prior systemic therapy must also include progression on brentuximab vedotin
Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; Phase 2: >= stage IB
Stage of disease according to TNMB classification
Pathology report must be diagnostic or be consistent with MF/SS criteria
SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria
For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used
Measurable disease per modified severity weighted assessment tool (mSWAT) and/or
Sezary count
Baseline skin biopsy taken within 6 months available for central review submission
Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria
Measurable and/or evaluable disease per Lugano Classification
Absolute neutrophil count (ANC) >= 1000/mm^3
Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
Platelets >= 100,000/mm^3
Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
Total serum bilirubin =< 2.2 mg/dL
Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) =< 2 x ULN
Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula
If not receiving anticoagulants: international normalized ratio (INR) AND prothrombin (PT) =< 1.5 x ULN
If on anticoagulant therapy: PT must be within therapeutic range of intended used of anticoagulants
Female of childbearing potential: negative urine or serum pregnancy test
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female of child bearing potential: willing to use 2 methods of birth control or be
Childbearing potential defined as not being surgically sterilized or have not been free from menses for > 1 year
surgically sterile, or abstain from heterosexual activity for the course of
the study through 90 days after the last dose of study medication
Male: use an adequate method of contraception starting with the first dose of study
therapy through 90 days after the last dose of study therapy

Exclusion Criteria

Immunotherapy with immune checkpoint inhibitors, cell-based therapies, or cancer vaccines
Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)
Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy
Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy
Any skin-directed therapy within 14 days prior to initiating protocol therapy
Any radiation therapy within 21 days prior to initiating protocol therapy
Immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions to this criterion
Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days
Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalent
Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy
History of pneumonitis (non-infectious) that required steroids or current pneumonitis
Disease free of prior malignancies for >= 5 years with the exception of
Currently treated squamous cell and basal cell carcinoma of the skin
Carcinoma in situ of the cervix, or
Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision or
Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured, or
Any other malignancy that has/have been curatively treated with surgery and/or localized radiation
Female only: pregnant or lactating
Prior stem cell transplantation
Acute infection requiring systemic treatment
Known history of human immunodeficiency virus (HIV) infection
Allergic reaction/ hypersensitivity to thalidomide or to the excipients contained in
Active hepatitis B or C infection
the formulation of durvalumab
Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy
Current peripheral neuropathy >= grade 2
Renal failure requiring hemodialysis or peritoneal dialysis
Unstable cardiac disease as defined by one of the following
Cardiac events such as myocardial infarction (MI) within the past 6 months
NYHA (New York Heart Association) heart failure class III-IV
Uncontrolled atrial fibrillation or hypertension
Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment; the following are exceptions to this criterion
Vitiligo or alopecia
Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or
Psoriasis not requiring systemic treatment
History of primary immunodeficiency
Major surgery (as defined by the investigator) within the 28 days prior to the first
Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide
dose of study treatment
Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/psychological issues, etc
In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note